Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010, Article ID 394913, 5 pages
http://dx.doi.org/10.1155/2010/394913
Research Article

Repeated Intraperitoneal ๐›ผ -Radioimmunotherapy of Ovarian Cancer in Mice

1Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden
2PET and Cyclotron Unit, Rigshospitalet, Copenhagen, Denmark

Received 15 April 2009; Accepted 1 September 2009

Academic Editor: Maurie M. Markman

Copyright © 2010 Jörgen Elgqvist et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [18 citations]

The following is the list of published articles that have cited the current article.

  • Jorgen Elgqvist, Daniel Ahlberg, Hakan Andersson, Holger Jensen, Bengt R Johansson, Helena Kahu, Marita Olsson, and Sture Lindegren, “Intraperitoneal Alpha-Radioimmunotherapy of Advanced Ovarian Cancer in Nude Mice Using Different High Specific Activities.,” World journal of oncology, vol. 1, no. 3, pp. 101–110, 2010. View at Publisher ยท View at Google Scholar
  • D. Scott Wilbur, Ming-Kuan Chyan, Donald K. Hamlin, H Holly Nguyen, and Robert L. Vessella, “Reagents for Astatination of Biomolecules. 5. Evaluation of Hydrazone Linkers in At-211- and I-125-Labeled closo-Decaborate(2-) Conjugates of Fab ' as a Means of Decreasing Kidney Retention,” Bioconjugate Chemistry, vol. 22, no. 6, pp. 1089–1102, 2011. View at Publisher ยท View at Google Scholar
  • Karen J. Wong, Kwamena E. Baidoo, Tapan K. Nayak, Kayhan Garmestani, Martin W. Brechbiel, and Diane E. Milenic, “In vitro and in vivo pre-clinical analysis of a F(ab')(2) fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers,” Ejnmmi Research, vol. 1, 2011. View at Publisher ยท View at Google Scholar
  • Helen Heyerdahl, Nasir Abbas, Ellen Mengshoel Brevik, Camilla Mollatt, and Jostein Dahle, “Fractionated Therapy of HER2-Expressing Breast and Ovarian Cancer Xenografts in Mice with Targeted Alpha Emitting Th-227-DOTA-p-benzyl-trastuzumab,” Plos One, vol. 7, no. 8, 2012. View at Publisher ยท View at Google Scholar
  • Christian Rauch, Christof Seidl, Martin Schlapschy, Arne Skerra, Alfred Morgenstern, Frank Bruchertseifer, and Reingard Senekowitsch-Schmidtke, “High molecular mass radioimmunoconjugates are promising for intraperitoneal alpha-emitter immunotherapy due to prolonged retention in the peritoneum,” Nuclear Medicine And Biology, vol. 39, no. 5, pp. 617–627, 2012. View at Publisher ยท View at Google Scholar
  • Markus Essler, Florian C. Gaertner, Frauke Neff, Birgit Blechert, Reingard Senekowitsch-Schmidtke, Frank Bruchertseifer, Alfred Morgenstern, and Christof Seidl, “Therapeutic efficacy and toxicity of Ac-225-labelled vs. Bi-213-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis,” European Journal Of Nuclear Medicine And Molecular Imaging, vol. 39, no. 4, pp. 602–612, 2012. View at Publisher ยท View at Google Scholar
  • Mario Vallon, Christof Seidl, Birgit Blechert, Zhoulei Li, Klaus-Peter Gilbertz, Anja Baumgart, Michaela Aichler, Annette Feuchtinger, Florian C. Gaertner, Frank Bruchertseifer, Alfred Morgenstern, Axel K. Walch, Reingard Senekowitsch-Schmidtke, and Markus Essler, “Enhanced efficacy of combined Bi-213-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest,” European Journal Of Nuclear Medicine And Molecular Imaging, vol. 39, no. 12, pp. 1886–1897, 2012. View at Publisher ยท View at Google Scholar
  • Anna M. E. Gustafsson, Tom Back, Jorgen Elgqvist, Lars Jacobsson, Ragnar Hultborn, Per Albertsson, Alfred Morgenstern, Frank Bruchertseifer, Holger Jensen, and Sture Lindegren, “Comparison of therapeutic efficacy and biodistribution of Bi-213- and At-211-labeled monoclonal antibody MX35 in an ovarian cancer model,” Nuclear Medicine And Biology, vol. 39, no. 1, pp. 15–22, 2012. View at Publisher ยท View at Google Scholar
  • Maneesh Jain, Suprit Gupta, Sukhwinder Kaur, Moorthy P. Ponnusamy, and Surinder K. Batra, “Emerging Trends for Radioimmunotherapy in Solid Tumors,” Cancer Biotherapy & Radiopharmaceuticals, pp. 130711061705008, 2013. View at Publisher ยท View at Google Scholar
  • Christof Seidl, and Markus Essler, “Radioimmunotherapy for peritoneal cancers,” Immunotherapy, vol. 5, no. 4, pp. 395–405, 2013. View at Publisher ยท View at Google Scholar
  • François Guérard, Jean-François Gestin, and Martin W. Brechbiel, “ Production of [ 211 At]-Astatinated Radiopharmaceuticals and Applications in Targeted α-Particle Therapy ,” Cancer Biotherapy & Radiopharmaceuticals, vol. 28, no. 1, pp. 1–20, 2013. View at Publisher ยท View at Google Scholar
  • Ruby F. Meredith, Julien Torgue, Michael T. Azure, Sui Shen, Souheil Saddekni, Eileen Banaga, Ronda Carlise, Patty Bunch, Daniel Yoder, and Ronald Alvarez, “ Pharmacokinetics and Imaging of 212 Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients ,” Cancer Biotherapy & Radiopharmaceuticals, pp. 131114064413002, 2013. View at Publisher ยท View at Google Scholar
  • Sophie E. Eriksson, Tom Back, Erika Elgstrom, Holger Jensen, Rune Nilsson, Sture Lindegren, and Jan Tennvall, “Successful radioimmunotherapy of established syngeneic rat colon carcinoma with (211) At-mAb,” Ejnmmi Research, vol. 3, 2013. View at Publisher ยท View at Google Scholar
  • Christof Seidl, “Radioimmunotherapy with a- particle- emitting radionuclides,” Immunotherapy, vol. 6, no. 4, pp. 431–458, 2014. View at Publisher ยท View at Google Scholar
  • Jonathan G. Sham, Forrest M. Kievit, John R. Grierson, Peter A. Chiarelli, Robert S. Miyaoka, Miqin Zhang, Raymond S. Yeung, Satoshi Minoshima, and James O. Park, “Glypican-3-Targeting F(ab ')2 for Zr-89 PET of Hepatocellular Carcinoma,” Journal Of Nuclear Medicine, vol. 55, no. 12, pp. 2032–2037, 2014. View at Publisher ยท View at Google Scholar
  • Sture Lindegren, Luciana N. S. Andrade, Tom Bäck, Camila Maria L. Machado, Bruno Brasil Horta, Carlos Buchpiguel, Ana Maria Moro, Oswaldo Keith Okamoto, Lars Jacobsson, Elin Cederkrantz, Kohshin Washiyama, Emma Aneheim, Stig Palm, Holger Jensen, Maria Carolina B. Tuma, Roger Chammas, Ragnar Hultborn, and Per Albertsson, “Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200,” Plos One, vol. 10, no. 5, pp. e0126298, 2015. View at Publisher ยท View at Google Scholar
  • Michael B. Tomblyn, Michael J. Katin, and Paul E. Wallner, “The New Golden Era for Radioimmunotherapy: Not Just for Lymphomas Anymore,” Cancer Control, vol. 20, no. 1, pp. 60–71, 2017. View at Publisher ยท View at Google Scholar
  • Anna Gustafsson-Lutz, Tom Bäck, Emma Aneheim, Ragnar Hultborn, Stig Palm, Lars Jacobsson, Alfred Morgenstern, Frank Bruchertseifer, Per Albertsson, and Sture Lindegren, “Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model,” EJNMMI Research, vol. 7, no. 1, 2017. View at Publisher ยท View at Google Scholar